Godavari Drugs Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 3/6
Godavari Drugs has been growing earnings at an average annual rate of 20.1%, while the Pharmaceuticals industry saw earnings growing at 16.5% annually. Revenues have been growing at an average rate of 14.6% per year. Godavari Drugs's return on equity is 12%, and it has net margins of 2.7%.
Key information
20.1%
Earnings growth rate
20.1%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 14.6% |
Return on equity | 12.0% |
Net Margin | 2.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Godavari Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,558 | 42 | 51 | 0 |
30 Sep 23 | 1,521 | 37 | 51 | 0 |
30 Jun 23 | 1,533 | 37 | 50 | 0 |
31 Mar 23 | 1,600 | 38 | 50 | 0 |
31 Dec 22 | 1,670 | 37 | 48 | 0 |
30 Sep 22 | 1,614 | 44 | 49 | 0 |
30 Jun 22 | 1,595 | 47 | 51 | 0 |
31 Mar 22 | 1,613 | 52 | 51 | 0 |
31 Dec 21 | 1,496 | 53 | 51 | 0 |
30 Sep 21 | 1,491 | 49 | 49 | 0 |
30 Jun 21 | 1,414 | 47 | 44 | 0 |
31 Mar 21 | 1,228 | 41 | 40 | 0 |
31 Dec 20 | 1,144 | 36 | 37 | 0 |
30 Sep 20 | 1,072 | 31 | 35 | 0 |
30 Jun 20 | 993 | 24 | 34 | 0 |
31 Mar 20 | 958 | 20 | 35 | 0 |
31 Dec 19 | 960 | 16 | 36 | 0 |
30 Sep 19 | 947 | 15 | 36 | 0 |
30 Jun 19 | 897 | 15 | 36 | 0 |
31 Mar 19 | 836 | 12 | 35 | 0 |
31 Dec 18 | 795 | 12 | 31 | 0 |
30 Sep 18 | 691 | 10 | 29 | 0 |
30 Jun 18 | 686 | 9 | 28 | 0 |
31 Mar 18 | 644 | 8 | 27 | 0 |
31 Dec 17 | 605 | 11 | 26 | 0 |
30 Sep 17 | 621 | 11 | 26 | 0 |
30 Jun 17 | 651 | 15 | 25 | 0 |
31 Mar 17 | 756 | 18 | 24 | 0 |
31 Dec 16 | 795 | 14 | 24 | 0 |
30 Sep 16 | 798 | 13 | 23 | 0 |
30 Jun 16 | 765 | 12 | 22 | 0 |
31 Mar 16 | 711 | 14 | 22 | 0 |
31 Dec 15 | 654 | 19 | 26 | 2 |
30 Sep 15 | 670 | 27 | 26 | 2 |
30 Jun 15 | 647 | 38 | 26 | 2 |
31 Mar 15 | 548 | 36 | 21 | 0 |
31 Dec 14 | 421 | 37 | 22 | 2 |
30 Sep 14 | 266 | 29 | 20 | 2 |
30 Jun 14 | 144 | 17 | 19 | 2 |
31 Mar 14 | 94 | 16 | 20 | 2 |
31 Dec 13 | 103 | 7 | 15 | 0 |
30 Sep 13 | 108 | 9 | 14 | 0 |
30 Jun 13 | 95 | 12 | 14 | 0 |
Quality Earnings: 530317 has high quality earnings.
Growing Profit Margin: 530317's current net profit margins (2.7%) are higher than last year (2.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530317's earnings have grown significantly by 20.1% per year over the past 5 years.
Accelerating Growth: 530317's earnings growth over the past year (13.3%) is below its 5-year average (20.1% per year).
Earnings vs Industry: 530317 earnings growth over the past year (13.3%) did not outperform the Pharmaceuticals industry 22.7%.
Return on Equity
High ROE: 530317's Return on Equity (12%) is considered low.